文献速递主动脉疾病

无并发症孤立性腹主动脉夹层的最佳药物治疗与血管腔内主动脉修复比较

Optimal medical treatment versus endovascular aortic repair in uncomplicated isolated abdominal aortic dissection.
PubMed 文献 · J Vasc Surg · 2022-11-01

该回顾性研究纳入2011年1月至2021年7月单中心连续96例无并发症孤立性腹主动脉夹层患者,初始53.1%(51/96)接受最佳药物治疗(OMT),46.9%(45/96)接受血管腔内主动脉修复(EVAR)。随访中OMT组夹层进展率高于EVAR组(10例[19.6%] vs 2例[4.5%],P=0.03),长期死亡率8.4%、随访主动脉干预率9.5%,两组无显著差异。

要点

  • 无并发症孤立性腹主动脉夹层初始OMT占53.1%(51/96),EVAR占46.9%(45/96)。
  • 随访中夹层进展率OMT组19.6%(10例)高于EVAR组4.5%(2例),P=0.03。
  • 长期死亡率8.4%、随访主动脉干预率9.5%,两组间无显著差异。

核心结论

  • 无并发症孤立性腹主动脉夹层可通过OMT联合定期监测安全处理,尽管存在疾病进展风险;与OMT相比,EVAR可显著预防夹层进展;对于解剖适合、夹层进展且对OMT无反应的患者,抢先EVAR是安全可行的选择。

研究设计与样本

  • 回顾性研究,纳入2011年1月至2021年7月单中心连续96例无并发症孤立性腹主动脉夹层患者,采用标准单变量和生存分析方法。

主要发现

  • 初始53.1%(51/96)接受OMT,46.9%(45/96)接受EVAR。
  • OMT组无院内死亡;随访中3例死亡,3例后续需血管腔内治疗、2例需外科手术。
  • EVAR组1例住院期间死亡;9例术后内漏,1例需再干预;随访中5例死亡,4例需再手术(1例外科手术、3例血管腔内治疗)。
  • 总体长期死亡率8.4%,随访主动脉干预率9.5%(中位随访54个月,四分位距33-81个月),两组间无显著差异。
  • 12例(12.6%)出现夹层进展,OMT组高于EVAR组(10例[19.6%] vs 2例[4.5%],P=0.03)。

临床怎么用

  • 作者认为无并发症孤立性腹主动脉夹层可通过OMT联合定期监测安全处理,尽管存在疾病进展风险。
  • 作者认为与OMT相比,EVAR可显著预防夹层进展。
  • 作者认为对于解剖适合、夹层进展且对OMT无反应的患者,抢先EVAR是安全可行的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the results of optimal medical treatment (OMT) and endovascular aortic repair (EVAR) in patients with uncomplicated isolated abdominal aortic dissection (IAAD). METHODS: A retrospective review of 96 consecutive patients with uncomplicated IAAD (uIAAD) managed at a single tertiary vascular unit between January 2011 and July 2021 was conducted. Standard methods for univariate and survival analyses were used. The primary outcomes were all-cause mortality. Secondary end points included uIAAD progression, interventional complications, and follow-up aortic intervention. RESULTS: Initially, 53.1% of patients (51/96) were managed with OMT. No in-hospital deaths occurred. During follow-up, three patients died, and three and two patients who were initially managed with OMT subsequently required endovascular treatment and surgical management, respectively. Initially, 46.9% of patients (45/96) underwent EVAR. One patient died during hospital admission; nine patients had an endoleak after operation and one needed reintervention. Furthermore, during follow-up, five patients died; four patients needed reoperation, one surgery and three endovascular treatments. The overall long-term mortality was 8.4%, and follow-up aortic intervention rate was 9.5% (median follow-up, 54 months; interquartile range, 33-81 months) with no significant difference between groups. Of note, 12 patients (12.6%) suffered uIAAD progression, which was higher in the OMT group than EVAR group (10 [19.6%] vs 2 [4.5%]; P = .03). CONCLUSIONS: uIAAD may be managed safely by OMT with regular surveillance, despite the risk of disease progression. Compared with OMT, EVAR could significantly prevent uIAAD progression. For anatomically suitable patients with uIAAD progression and who are unresponsive to OMT, pre-emptive EVAR is a safe and feasible option.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Su S, Liu J, Wang C, et al. Optimal medical treatment versus endovascular aortic repair in uncomplicated isolated abdominal aortic dissection. J Vasc Surg. 2022. PMID: 36332808. doi:10.1016/j.jvs.2022.10.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。